Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
International Journal of Surgical Pathology|June 24, 2020
Surgical Pathology Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy With Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder: A Contemporary AnalysisJoshua Kagan, Mehrdad Alemozaffar, Bradley Carthon, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 12, 2021
Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?Frank C Cackowski, Brandon Mahal, Elisabeth I Heath, et al.
The Oncologist|March 8, 2021
Prostate Cancer: Community Education and Disparities in Diagnosis and TreatmentBradley Carthon, Hannah C Sibold, Shannon Blee, et al.
Human Pathology|June 27, 2025
Somatic yolk sac tumors in the urinary tract: A form of rare divergent differentiationNicholas Tedrow, Kenneth Ogan, Shreyas Joshi, et al.
Urology|April 16, 2018
The Clinical Course of Patients With Prostate-Specific Antigen ≥100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen ScreeningAndrew K Leung, Lee Hugar, Dattatraya Patil, et al.
American Journal of Nuclear Medicine and Molecular Imaging|July 8, 2021
Exploratory study of 18F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancerAkinyemi A Akintayo, Mehmet A Bilen, Olayinka A Abiodun-Ojo, et al.
Frontiers in Oncology|February 18, 2021
Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case ReportMehmet A Bilen, James F Jiang, Caroline S Jansen, et al.
The Oncologist|June 7, 2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment OptionsKatherine Emilie Rhoades Smith, Jacqueline Theresa Brown, Limeng Wan, et al.
Investigational New Drugs|January 6, 2015
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancerDaniel P Petrylak, Jitendra G Gandhi, William R Clark, et al.
Clinical and Translational Radiation Oncology|December 9, 2020
Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer DatabaseJames Robert Janopaul-Naylor, Jim Zhong, Yuan Liu, et al.
Pageof 2